Source: BioSpace

Cygnus Technologies, Inc.: Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Dyadic International Inc. ("Dyadic", or the "Company") (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins ("HCP") from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila).

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100